Boston Scientific and Chengdu New Radiomedicine Technology Co Ltd on Friday signed a cooperation agreement on equity investment, technology transfer and localized production in Chengdu, Sichuan province.

It is the first time the US based global medical technology leader has cooperated with a local Chinese company in technology transfer and localized production, marking an important milestone for the company to accelerate its localization process and facilitate its strategic layout in western China.

According to the agreement, Boston Scientific will transfer TheraSphere Y90 glass microsphere technology to the Chinese company, known as CNRT, for internal radiotherapy of liver cancer, in order to accelerate the introduction and localized production of this medical product to benefit liver cancer patients in China.

Speaking at a signing ceremony, June Chang, president of Boston Scientific China, said: "In the future, we hope to deepen cooperation with more local partners, go hand in hand to jointly accelerate the integration of China with international medical innovation; make high-quality medical resources more accessible and timely, and contribute to realizing the vision of a 'Healthy China' with a never-changing commitment to 'Advancing science for life'."

Liver cancer is the fourth most common and the second most deadly malignant tumor seen in China.

In October 2019, Boston Scientific and the city of Chengdu signed an investment cooperation agreement for a "second headquarters" in China.

Since then, Boston Scientific's western China strategy has made rapid progress. In September 2020, the so-called "second headquarters" was officially put into operation in Chengdu.